PubRank

Timothy R Morgan

Author PubWeight™ 130.04‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 16.21
2 Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008 9.33
3 A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013 6.19
4 Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2008 6.15
5 Alcoholic hepatitis. N Engl J Med 2009 4.98
6 Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2009 4.90
7 Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004 4.27
8 Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006 3.92
9 Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004 3.46
10 The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006 3.13
11 Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005 3.09
12 Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010 2.96
13 Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005 2.63
14 Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2010 2.47
15 Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2006 2.12
16 Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology 2011 1.98
17 Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012 1.95
18 Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 2015 1.94
19 Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005 1.93
20 Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2010 1.83
21 Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009 1.80
22 Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2006 1.76
23 Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol 2007 1.71
24 Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. J Gastroenterol Hepatol 2010 1.68
25 Epidemiology of alcoholic liver disease. Semin Liver Dis 2004 1.66
26 Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008 1.66
27 Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology 2013 1.63
28 Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2012 1.55
29 Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology 2010 1.52
30 Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2009 1.46
31 Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2006 1.38
32 Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2009 1.35
33 A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011 1.33
34 Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology 2002 1.27
35 Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 2011 1.20
36 Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol 2006 1.18
37 HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology 2006 1.13
38 Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Hepatology 2012 1.12
39 Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. Am J Physiol Gastrointest Liver Physiol 2010 1.08
40 Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 2009 1.08
41 Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2008 1.07
42 The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. J Hepatol 2008 1.04
43 An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One 2011 1.04
44 Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice? J Clin Gastroenterol 2008 0.99
45 Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol 2008 0.98
46 Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 2011 0.98
47 Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 2011 0.95
48 Liver disease in alcohol and hepatitis C. Best Pract Res Clin Gastroenterol 2003 0.94
49 Alcoholic liver disease - Hepatocellular carcinoma transformation. J Gastrointest Oncol 2012 0.92
50 Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology 2008 0.91
51 Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2009 0.88
52 Brief report: genetics of alcoholic cirrhosis-GenomALC multinational study. Alcohol Clin Exp Res 2015 0.83
53 Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease. Nutr Res 2013 0.80
54 Alcohol and hepatitis C. Dig Dis 2005 0.80
55 IL28B-genotype testing now and in the era of direct-acting antiviral agents. Clin Gastroenterol Hepatol 2010 0.80
56 Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol 2012 0.78
57 Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor. Cell Immunol 2009 0.77
58 Update on recently approved treatments for hepatitis C. Curr Treat Options Gastroenterol 2014 0.76
59 Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C. Am J Gastroenterol 2010 0.76
60 Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response? Hepatology 2007 0.75
61 Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology 2014 0.75
62 CYP2E1 inhibition enhances mallory body formation. Exp Mol Pathol 2005 0.75